TYLER.HEALTH develops a next-generation continuous glucose monitoring (CGM) sensor paired with a companion app that tracks blood glucose in real time and provides hyper-personalized feedback on how nutrition, exercise, and sleep affect metabolic health. The product combines sensor hardware and advanced analytics to translate biometric data into understandable, actionable insights for weight management, cognitive performance, and chronic disease prevention. The company planned a beta launch of 1,000 CGM sensors and an app release in December 2021. TYLER.HEALTH raised €500,000 in a pre-seed round to fund the beta rollout, accelerate app development, and support further research and product innovation. Leadership includes CEO and co-founder Ignas Survila and CTO/co-founder Edvinas Baublys, with Kasparas Aleknavičius, MD, as Chief of Science and Albinas Plėšnys as Chief of Data. The team emphasizes leveraging advanced data analytics to provide continuous, personalized metabolic-health recommendations and aims to scale access to address global metabolic health challenges.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Aug 2021